{"id":"smartject-device-delivery-of-golimumab","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"10-15","effect":"Nasopharyngitis"},{"rate":"5-10","effect":"Headache"},{"rate":"1-3","effect":"Increased infection risk (serious infections)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Golimumab is a fully human monoclonal antibody that targets TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking TNF-α, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. The Smartject device is an auto-injector delivery system that enables patient self-administration of the drug.","oneSentence":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:47.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Ulcerative colitis"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT02155335","phase":"PHASE4","title":"Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-07-01","conditions":"Ulcerative Colitis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Smartject Device delivery of Golimumab","genericName":"Smartject Device delivery of Golimumab","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}